{"parse":{"title":"Paediatric-use marketing authorisation","pageid":33654045,"revid":523728855,"text":{"*":"<div class=\"mw-parser-output\"><p><b>Paediatric-use marketing authorisations</b> (<b>PUMA</b>) are granted by the <a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Medicines Agency</a> (EMA) for medical products that are intended exclusively for <a href=\"/wiki/Paediatric\" class=\"mw-redirect\" title=\"Paediatric\">paediatric</a> use, that is, for use in patients younger than 18 years. Like ordinary EMA marketing authorisations, a PUMA approval is valid in all countries of the <a href=\"/wiki/European_Economic_Area\" title=\"European Economic Area\">European Economic Area</a> (the <a href=\"/wiki/European_Union\" title=\"European Union\">European Union</a> as well as Iceland, Liechtenstein and Norway). The PUMA process was established to make it more profitable for pharmaceutical companies to market drugs for children. For this purpose, new data used for PUMA approved drugs are protected for 10 years, and the applications are partially exempt from fees.<sup id=\"cite_ref-1\" class=\"reference\"><a href=\"#cite_note-1\">&#91;1&#93;</a></sup>\n</p><p>In September 2011, the first drug was approved under this process. It was Buccolam, a <a href=\"/wiki/Cheek\" title=\"Cheek\">buccal</a> application form of <a href=\"/wiki/Midazolam\" title=\"Midazolam\">midazolam</a> for the treatment of <a href=\"/wiki/Seizures\" class=\"mw-redirect\" title=\"Seizures\">seizures</a>.<sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Paediatric-use_marketing_authorisation&amp;action=edit&amp;section=1\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist\" style=\"list-style-type: decimal;\">\n<div class=\"mw-references-wrap\"><ol class=\"references\">\n<li id=\"cite_note-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-1\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/09/WC500112071.pdf\">\"Questions and answers on the paediatric use marketing authorisation (PUMA)\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Medicines Agency</a>. 13 September 2011.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Questions+and+answers+on+the+paediatric+use+marketing+authorisation+%28PUMA%29&amp;rft.pub=European+Medicines+Agency&amp;rft.date=2011-09-13&amp;rft_id=http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FOther%2F2011%2F09%2FWC500112071.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APaediatric-use+marketing+authorisation\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Committee_meeting_report/2011/07/WC500108232.pdf\">\"Monthly Report\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <a href=\"/wiki/Committee_for_Medicinal_Products_for_Human_Use\" title=\"Committee for Medicinal Products for Human Use\">Committee for Medicinal Products for Human Use</a> (CHMP). 5 July 2011. p.&#160;1.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Monthly+Report&amp;rft.pages=1&amp;rft.pub=Committee+for+Medicinal+Products+for+Human+Use+%28CHMP%29&amp;rft.date=2011-07-05&amp;rft_id=http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FCommittee_meeting_report%2F2011%2F07%2FWC500108232.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APaediatric-use+marketing+authorisation\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">PR Newswire (6 September 2011). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.wallstreet-online.de/nachricht/3364595-viropharma-s-buccolam-midazolam-oromucosal-solution-granted-european-marketing-authorization-for-treatment-of-acute-seizures\">\"ViroPharma's Buccolam (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures\"</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=ViroPharma%27s+Buccolam+%28Midazolam%2C+Oromucosal+Solution%29+Granted+European+Marketing+Authorization+for+Treatment+of+Acute+Seizures&amp;rft.date=2011-09-06&amp;rft.au=PR+Newswire&amp;rft_id=http%3A%2F%2Fwww.wallstreet-online.de%2Fnachricht%2F3364595-viropharma-s-buccolam-midazolam-oromucosal-solution-granted-european-marketing-authorization-for-treatment-of-acute-seizures&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APaediatric-use+marketing+authorisation\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div></div>\n<p><br />\n</p>\n<table class=\"metadata plainlinks stub\" role=\"presentation\" style=\"background:transparent\"><tbody><tr><td><a href=\"/wiki/File:Emoji_u1f48a.svg\" class=\"image\"><img alt=\"Stub icon\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/f/fe/Emoji_u1f48a.svg/30px-Emoji_u1f48a.svg.png\" width=\"30\" height=\"30\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/f/fe/Emoji_u1f48a.svg/45px-Emoji_u1f48a.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/f/fe/Emoji_u1f48a.svg/60px-Emoji_u1f48a.svg.png 2x\" data-file-width=\"128\" data-file-height=\"128\" /></a></td><td><i>This <a href=\"/wiki/Pharmacology\" title=\"Pharmacology\">pharmacology</a>-related article is a <a href=\"/wiki/Wikipedia:Stub\" title=\"Wikipedia:Stub\">stub</a>. You can help Wikipedia by <a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Paediatric-use_marketing_authorisation&amp;action=edit\">expanding it</a>.</i><div class=\"plainlinks hlist navbar mini\" style=\"position: absolute; right: 15px; display: none;\"><ul><li class=\"nv-view\"><a href=\"/wiki/Template:Pharma-stub\" title=\"Template:Pharma-stub\"><abbr title=\"View this template\">v</abbr></a></li><li class=\"nv-talk\"><a href=\"/wiki/Template_talk:Pharma-stub\" title=\"Template talk:Pharma-stub\"><abbr title=\"Discuss this template\">t</abbr></a></li><li class=\"nv-edit\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Template:Pharma-stub&amp;action=edit\"><abbr title=\"Edit this template\">e</abbr></a></li></ul></div></td></tr></tbody></table>\n\n<!-- \nNewPP limit report\nParsed by mw1300\nCached time: 20180903234547\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.084 seconds\nReal time usage: 0.109 seconds\nPreprocessor visited node count: 186/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 8123/2097152 bytes\nTemplate argument size: 102/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 3467/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.038/10.000 seconds\nLua memory usage: 2.09 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%   90.447      1 -total\n 79.02%   71.467      1 Template:Reflist\n 59.48%   53.794      2 Template:Cite_web\n 20.91%   18.909      1 Template:Pharma-stub\n 17.52%   15.845      1 Template:Asbox\n  6.26%    5.660      1 Template:Cite_news\n  2.11%    1.905      1 Template:Main_other\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:33654045-0!canonical and timestamp 20180903234547 and revision id 523728855\n -->\n</div>"},"langlinks":[{"lang":"de","url":"https://de.wikipedia.org/wiki/Verordnung_%C3%BCber_Kinderarzneimittel#_Zulassung_f\u00fcr_die_p\u00e4diatrische_Verwendung","langname":"German","autonym":"Deutsch","*":"Verordnung \u00fcber Kinderarzneimittel# Zulassung f\u00fcr die p\u00e4diatrische Verwendung"}],"categories":[{"sortkey":"","*":"Health_and_the_European_Union"},{"sortkey":"","hidden":"","*":"All_stub_articles"},{"sortkey":"","*":"Pharmacology_stubs"}],"links":[{"ns":10,"exists":"","*":"Template:Pharma-stub"},{"ns":0,"exists":"","*":"Cheek"},{"ns":0,"exists":"","*":"Committee for Medicinal Products for Human Use"},{"ns":0,"exists":"","*":"European Economic Area"},{"ns":0,"exists":"","*":"European Medicines Agency"},{"ns":0,"exists":"","*":"European Union"},{"ns":0,"exists":"","*":"Midazolam"},{"ns":0,"exists":"","*":"Paediatric"},{"ns":0,"exists":"","*":"Pharmacology"},{"ns":0,"exists":"","*":"Seizures"},{"ns":4,"exists":"","*":"Wikipedia:Stub"},{"ns":11,"exists":"","*":"Template talk:Pharma-stub"}],"templates":[{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Cite news"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Pharma-stub"},{"ns":10,"exists":"","*":"Template:Asbox"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Asbox"},{"ns":828,"exists":"","*":"Module:Buffer"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Navbar"}],"images":["Emoji_u1f48a.svg"],"externallinks":["http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/09/WC500112071.pdf","http://www.ema.europa.eu/docs/en_GB/document_library/Committee_meeting_report/2011/07/WC500108232.pdf","http://www.wallstreet-online.de/nachricht/3364595-viropharma-s-buccolam-midazolam-oromucosal-solution-granted-european-marketing-authorization-for-treatment-of-acute-seizures"],"sections":[{"toclevel":1,"level":"2","line":"References","number":"1","index":"1","fromtitle":"Paediatric-use_marketing_authorisation","byteoffset":1736,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Paediatric-use marketing authorisation","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q7124059"}]}}